

Day 1

ORAL PROGRAM MONDAY, SEPTEMBER 13	
0820-0830	THEME OF THE DAY Guus Rimmelzwaan, <i>The University of Veterinary Medicine Hannover</i>
0830-0930	OPENING SESSION *LIVE* Session Chair and Introduction: Manon Cox, <i>ISV/NextWaveBio</i> Welcome: Ted Ross, President, <i>ISV</i> KEYNOTE SPEAKER 1: Mind the GAPP: A Vision for Ending Pandemics W. Ian Lipkin, <i>Columbia University</i> Q&A
0930-1100	PLENARY SESSION 1: NEW VACCINES ON THE HORIZON
5 min	Session Introduction Chairs: David Weiner, <i>The Wistar Institute</i> ; Sanjay Phogat, <i>GSK</i>
25min	RSV Immunization Approaches for Infants and Children Jon Heinrichs, <i>Sanofi Pasteur</i>
25 min	HA Stalk and NA-Based Next Generation Influenza Virus Vaccines Florian Krammer, <i>Icahn School of Medicine at Mount Sinai</i>
25 min	Efficient Selection of Tumor Associated Neoantigens in the Design of Personalized Cancer Vaccines Michael Princiotta, <i>EpiVax Therapeutics</i>
1100-1130	QUESTION AND ANSWER SESSION ON PLENARY SESSION 1 *LIVE* Chairs: David Weiner, <i>The Wistar Institute</i> ; Sanjay Phogat, <i>GSK</i>
1130-1200	POSTER SESSION 1
1200-1330	PLENARY SESSION 2: NEW DEVELOPMENTS IN TECHNOLOGY
5 min	Session Introduction Chair: Lenny Moise, <i>EpiVax</i> ; Amy Espeseth, <i>Merck</i>
25min	Computational Design of Nanoparticle Vaccines for Influenza Viruses, Coronaviruses, and Beyond Neil King, <i>University of Washington</i>
25 min	Delivery of mRNA Vaccines - Current Status and Future Opportunities Colin Pouton, <i>Monash University</i>
25 min	Vaxxas' High Density Micro-Projection Array Patch (HD-MAP) - Delivering the Future of Needle-Free Vaccination Angus Forster, <i>Vaxxas</i>
1330-1400	QUESTION AND ANSWER SESSION ON PLENARY SESSION 2 *LIVE* Chair: Lenny Moise, <i>EpiVax</i> ; Amy Espeseth, <i>Merck</i>
1400-1430	SELECT YOUR MASTERCLASS 1 - T-CELL IMMUNOLOGY Katherine Kedzierska, <i>University of Melbourne</i>
1430-1500	MEET THE FELLOWS 1 David Weiner, <i>The Wistar Institute</i> with Sarah Gilbert, <i>University of Oxford</i>
1500-1530	SELECT YOUR MASTERCLASS 2 - INNOVATION & MANUFACTURING OF COVID VACCINES Barry Buckland, <i>BiologicB</i>
1530-1600	MEET THE FELLOWS 2 Linda Klavinskis, <i>King's College London</i> with Xavier Saelens, <i>Ghent University</i>

Day 2

ORAL PROGRAM TUESDAY, SEPTEMBER 14

0820-0830	THEME OF THE DAY Laura Palomares, <i>National Autonomous University of Mexico</i>
0830-0910	KEYNOTE SPEAKER 2: Vaccine Diplomacy in a Time of Antiscience Peter Hotez, <i>National School of Tropical Medicine</i>
0910-1030	PLENARY SESSION 3: VACCINE MANUFACTURING & QUALITY CONTROL
5 min	Session Introduction Chair: Linda Lua, <i>Queensland University</i> ; Indresh Srivastava, <i>Novavax</i>
25min	Leveraging Vaccine Manufacturing and Quality Control Platforms for New Modalities, MassBiologics Experience Mireli Fino, <i>MassBiologics</i>
25 min	Vaccine Production in Emerging Economies, Challenges and Opportunities Sergio Valentinotti, <i>Liomont</i> and Esteben Corley, <i>mAbxience</i>
12 min	ORAL ABSTRACT 1 DNA Delivery of Immune-Focused SARS-CoV-2 Nanoparticle Vaccines Drives Rapid and Potent Immunogenicity and Achieves Single-Dose Protection Kevin Liaw, <i>The Wistar Institute</i>
12 min	ORAL ABSTRACT 2 An mRNA vaccine against SARS-CoV-2: Polyethylene Glycol-free, liposome-based vaccine candidate EG-COVID induces high levels of virus neutralizing antibodies H. Christian Hong, <i>EyeGene INC.</i>
1030-1100	QUESTION AND ANSWER SESSION ON PLENARY SESSION 3 *LIVE* Chair: Linda Lua, <i>Queensland University</i> ; Indresh Srivastava, <i>Novavax</i>
1100-1145	MEET THE FELLOWS 3 – EVERYTHING ABOUT ISV Moderator: Manon Cox, <i>ISV/NextWaveBio</i> Ted Ross, <i>ISV/University of Georgia</i> ; Denise Doolan, <i>ISV/James Cook University</i> ; Shan Lu, <i>ISV/UMMS</i>
1145-1230	POSTER SESSION 2
1230-1400	PLENARY SESSION 4: REGULATION IN TIMES OF PANDEMICS & VACCINE HESITANCY + ORAL ABSTRACT SELECTIONS
5 min	Session Introduction Chair: Laura Palomares, <i>National Autonomous University of Mexico</i> ; Lars Frelin <i>Karolinska Institutet</i>
25min	Global Regulation in Challenging Times: Pandemics and Health Urgency of Innovation Rogerio Gaspar, <i>WHO</i>
12 min	ORAL ABSTRACT 3 Perception of Vaccination of Filipino Mothers in the NCR Area Post-Dengvaxia Naomi Pompa, <i>University of Santo Tomas</i>
12 min	ORAL ABSTRACT 4 High Throughput Biosensor Technology to Establish Dosing Frequency and Concentration for an mRNA-LNP Genital Herpes Vaccine Lauren Hook, <i>University of Pennsylvania</i>
12 min	ORAL ABSTRACT 5 T Cell Epitope Content Comparison (EpiCC) Analysis Between PCV2 Vaccines and Field Strains Andres Gutierrez, <i>EpiVax</i>

12 min	ORAL ABSTRACT 6 Improved Protection Against Multidrug Pseudomonas Aeruginosa Following Administration of an Fc Engineered DNA-encoded Monoclonal Antibody (DMAb) with Enhanced Complement Activity Jihae Choi, <i>The Wistar Institute</i>
1400-1430	QUESTION AND ANSWER SESSION ON PLENARY SESSION 4 *LIVE* Chair: Laura Palomares, <i>National Autonomous University of Mexico</i>; Lars Frelin <i>Karolinska Institutet</i>
1500-1530	MEET THE FELLOWS 4 Margaret Liu, <i>ProTherImmune</i> with Gary Kobinger, <i>Laval University</i>
1530-1600	SELECT YOUR MASTERCLASS 3 - VACCINE CHARACTERIZATION AND ANALYTICS Indresh Srivastava, <i>Novavax</i>
1600-1700	ISV ANNUAL GENERAL MEETING *LIVE*

Day 3

ORAL PROGRAM WEDNESDAY, SEPTEMBER 15

0820-0830	THEME OF THE DAY Manon Cox, <i>ISV/NextWaveBio</i>
0830-0910	KEYNOTE SPEAKER 3: Preparing for the Next Pandemic in a One Health Approach Albert Osterhaus, <i>The University of Veterinary Medicine Hannover</i>
0910-1030	PLENARY SESSION 5: ONE WORLD; ONE HEALTH VETERINARY VACCINES
5 min	Session Introduction Chair: Alejandro Gil, <i>Sinergium</i> ; Randy Albrecht, <i>Icahn School of Medicine at Mount Sinai</i>
25min	The Research and Development of Veterinary Vaccines from a Biodefense and One Health Perspective Cyril Gay, <i>USDA ARS</i>
25 min	Next Generation Vaccine Platform: Polymersomes as Stable Nanocarriers for a Highly Immunogenic and Durable SARS-CoV-2 Spike Protein Subunit Vaccine Madhavan Nallani, <i>ACM Biolabs</i>
25 min	Innovation in Veterinary Vaccines: Our Experience in the Development of a Targeted Vaccine for BVDV and Virus Like Particles for FMDV Andres Wigdorovitz, <i>INTA -CONICET- Bioinnovo SA</i>
1030-1100	QUESTION AND ANSWER SESSION ON PLENARY SESSION 5 *LIVE* Chair: Alejandro Gil, <i>Sinergium</i> ; Randy Albrecht, <i>Icahn School of Medicine at Mount Sinai</i>
1100-1130	SELECT YOUR MASTERCLASS 4 – THE CONCEPTS OF GCP Janet Rose Rea, <i>AVM Biotechnology</i>
1200-1230	MEET THE FELLOWS 5 Annie De Groot, <i>EpiVax</i> with Tonya Villafana <i>AstraZeneca</i>
1230-1330	PLENARY SESSION 6: GLOBAL HEALTH AND VACCINE DEVELOPMENT
5 min	Session Introduction Chair: Linda Klavinskis <i>King's College London</i> ; Nathalie Garcon, <i>BioAster</i>
25min	Challenges in Establishing Vaccine Manufacturing from a Research Set Up Subhash Kapre, <i>Inventprise</i>
25 min	Correlates of Protection for COVID-19: What We've Learned So Far Peter Dull, <i>Bill & Melinda Gates Foundation</i>
1330-1400	QUESTION AND ANSWER SESSION ON PLENARY SESSION 6 *LIVE* Chair: Linda Klavinskis <i>King's College London</i> ; Nathalie Garcon, <i>BioAster</i>
1400-1415	CLOSING SESSION & 2022 ISV Congress Chair: Manon Cox, <i>ISV/NextWaveBio</i> Closing Remark: Denise Doolan, <i>ISV President for Next Term</i> 2022 ISV Congress: Joon Rhee, <i>Chonnam National University</i> ; Gary Kobinger, <i>Laval University</i> ; Shan Lu, <i>ISV/UMMS</i>